KBIOGATEWAY Raises Seed Funding for Functional Ingredients

South Korea's KBIOGATEWAY has successfully closed a Seed funding round, securing approximately 1.2 billion Korean won (USD 930,000). This capital injection is set to fuel the company's ambitious plans in the rapidly expanding functional ingredients market, particularly those targeting healthy and beautiful aging. The round was spearheaded by Korea Technology Finance Corporation, with significant contributions from venture capital firms BluePoint Partners and Y&Archer, underscoring strong investor confidence in KBIOGATEWAY's innovative approach.

Founded in 2025, KBIOGATEWAY is carving out a niche by focusing on the research and development of proprietary green-bio functional ingredients. At the heart of their innovation is DH24, a unique probiotic strain identified as Lactiplantibacillus plantarum DH24. This strain is engineered to offer dual benefits: aiding in body fat reduction and modulating inflammatory metabolic processes. This scientific foundation is crucial as the global nutraceutical and cosmeceutical markets continue to prioritize scientifically validated ingredients with demonstrable health outcomes.

The company's strategic vision is already yielding results, evidenced by its selection for the prestigious TIPS (Tech Incubator Program for Startup), a government initiative managed by the Ministry of SMEs and Startups. This recognition, coupled with prior success in securing 2.4 billion won through various government R&D and startup support programs, highlights KBIOGATEWAY's technological prowess and commercial viability. These achievements provide a robust validation of their business model and the potential of their core technology.

KBIOGATEWAY is actively leveraging the DH24 strain through its consumer brand, Diet Helper 24. This product line directly addresses the growing consumer demand for scientifically backed solutions for weight management and overall well-being. The company's CEO, Kyung-won Cho, brings a wealth of experience to the venture, having previously developed highly successful products in the probiotic sector, including the well-known Lactofit range. This proven track record is a significant asset as KBIOGATEWAY aims to scale its operations.

The newly acquired funding will be strategically deployed to accelerate critical business objectives. Key areas of investment include advancing the research and development pipeline for DH24-based products, significantly expanding manufacturing capabilities to meet anticipated demand, and initiating global clinical trials. Furthermore, the company plans to pursue international regulatory approvals, a vital step for global market penetration. This multi-pronged strategy is designed to solidify KBIOGATEWAY's position as a leader in the functional ingredient space.

“With this investment, we are empowered to significantly enhance our research, development, and commercialization efforts for DH24,” stated CEO Kyung-won Cho. “Our focus now sharpens on accelerating our global market entry, bringing our innovative solutions to a wider audience seeking effective and science-backed aging support.” The company's trajectory aligns with the broader market trend towards personalized nutrition and preventative health solutions, driven by an aging global population and increasing consumer health consciousness.